Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 10.66%6.55B | 7.79%4.83B | 10.46%3.14B | 18.16%5.92B | 19.76%4.48B | 19.72%2.84B | 19.13%5.01B | 3.74B | 2.38B | 69.84%4.21B |
Operating revenue | 10.66%6.55B | 7.79%4.83B | 10.46%3.14B | 18.16%5.92B | 19.76%4.48B | 19.72%2.84B | 19.13%5.01B | --3.74B | --2.38B | 69.84%4.21B |
Other operating revenue | 60.91%75.12M | 73.38%57.63M | 60.73%35.71M | -29.53%46.68M | --33.24M | -39.32%22.22M | 51.25%66.25M | ---- | --36.62M | 226.13%43.8M |
Total operating cost | 12.63%5.54B | 10.18%4.04B | 13.40%2.64B | 16.57%4.92B | 3.67B | 13.89%2.33B | 11.88%4.22B | 2.04B | 69.89%3.77B | |
Operating cost | 9.42%4.67B | 6.78%3.39B | 9.37%2.22B | 16.22%4.27B | --3.18B | 13.45%2.03B | 12.83%3.67B | ---- | --1.79B | 77.25%3.25B |
Operating tax surcharges | 41.68%39.91M | 30.04%27.5M | 49.48%18.92M | 52.53%28.17M | --21.14M | 41.85%12.66M | 80.33%18.47M | ---- | --8.92M | 52.53%10.24M |
Operating expense | 23.37%355.02M | 23.76%262.15M | 20.12%181.9M | 16.32%287.76M | --211.82M | 29.06%151.44M | 18.06%247.38M | ---- | --117.34M | 45.05%209.54M |
Administration expense | 23.43%258.04M | 16.54%197.19M | 34.39%121.31M | 21.04%209.06M | --169.2M | 25.78%90.26M | 13.76%172.72M | ---- | --71.76M | 7.62%151.83M |
Financial expense | 71.57%-12.29M | 26.64%-18.76M | 76.78%-8.73M | -27.72%-43.24M | ---25.57M | -393.43%-37.61M | -260.58%-33.86M | ---- | ---7.62M | 27.62%21.08M |
-Interest expense (Financial expense) | 22.99%20.18M | 28.49%16.2M | 34.53%10.79M | 46.28%16.41M | --12.61M | 63.98%8.02M | 84.13%11.22M | ---- | --4.89M | 9.99%6.09M |
-Interest Income (Financial expense) | -4.25%-26.28M | -29.52%-21.65M | -17.02%-14.36M | -55.82%-25.21M | ---16.71M | -78.97%-12.27M | -347.59%-16.18M | ---- | ---6.85M | -101.41%-3.61M |
Research and development | 35.24%231.89M | 59.52%178.03M | 31.90%101.22M | 18.52%171.46M | --111.61M | 27.01%76.74M | 14.65%144.67M | ---- | --60.42M | 65.70%126.19M |
Credit Impairment Loss | -109.25%-34.21M | -6.04%-30.22M | -55.63%-24.12M | -211.33%-16.35M | ---28.5M | -55.63%-15.5M | 76.98%-5.25M | ---- | ---9.96M | -128.53%-22.81M |
Asset Impairment Loss | -85.93%-23.28M | -22.40%-12.29M | -12.47%-7.9M | -29.12%-12.52M | ---10.04M | 22.85%-7.03M | -50.32%-9.7M | ---- | ---9.11M | -42.39%-6.45M |
Other net revenue | 88.04%-1.34M | 93.23%-2.91M | 98.65%-353.4K | 70.29%-11.21M | -43.02M | 4.93%-26.18M | -92.12%-37.72M | 0 | -27.53M | -203.86%-19.63M |
Fair value change income | ---- | ---- | ---- | 171.62%4.78M | --4.68M | 113.75%2M | -452.40%-6.67M | ---- | ---14.52M | 48,881.66%1.89M |
Invest income | 196.06%7.57M | 226.30%9.31M | 1,209.79%10.27M | 70.76%-7.89M | ---7.37M | -182.20%-925.38K | -879.44%-26.97M | ---- | --1.13M | 358.83%3.46M |
-Including: Investment income associates | -86.22%250.65K | 46.78%1.69M | -58.69%2.34M | 16.72%1.82M | --1.15M | 13,566.94%5.67M | 190.48%1.56M | ---- | --41.5K | 18.76%-1.72M |
Asset deal income | 142.76%2.33M | 156.52%3.75M | 158.40%3.71M | -435.15%-5.45M | ---6.63M | -225.48%-6.36M | 158.40%1.63M | ---- | ---1.95M | -272.99%-2.78M |
Other revenue | 76.39%46.25M | 449.69%26.54M | 979.26%17.69M | 183.64%26.22M | --4.83M | -76.18%1.64M | 30.91%9.24M | ---- | --6.88M | -78.70%7.06M |
Operating profit | 2.00%1.01B | 2.03%784.3M | 2.37%502.33M | 31.52%990.12M | 37.39%768.68M | 61.05%490.7M | 81.78%752.81M | 559.48M | 304.68M | 50.56%414.14M |
Add:Non operating Income | -41.31%145.9K | -54.37%74.24K | -64.04%50.74K | -85.52%248.58K | --162.72K | -89.68%141.11K | 9.71%1.72M | ---- | --1.37M | 214.95%1.57M |
Less:Non operating expense | -21.83%901.29K | -27.06%766.79K | -88.71%41.18K | -6.43%1.15M | --1.05M | -30.23%364.81K | -14.16%1.23M | ---- | --522.9K | 387.47%1.44M |
Total profit | 2.01%1.01B | 2.06%783.61M | 2.42%502.34M | 31.32%989.21M | 37.13%767.8M | 60.53%490.47M | 81.84%753.29M | 559.91M | 305.53M | 50.49%414.27M |
Less:Income tax cost | -11.48%152.5M | -10.02%122.77M | -15.94%75.15M | 42.98%172.29M | --136.44M | 75.36%89.4M | 100.62%120.5M | ---- | --50.98M | 12.14%60.06M |
Net profit | 4.86%856.62M | 4.67%660.84M | 6.51%427.19M | 29.10%816.93M | 33.76%631.36M | 57.56%401.07M | 78.65%632.8M | 472M | 254.55M | 59.76%354.21M |
Net profit from continuing operation | 4.86%856.62M | 4.67%660.84M | 6.51%427.19M | 29.10%816.93M | --631.36M | 57.56%401.07M | 78.65%632.8M | ---- | --254.55M | 59.76%354.21M |
Less:Minority Profit | 50.33%16.81M | 34.19%11.23M | 54.82%7.55M | 92.78%11.18M | --8.37M | 67.20%4.87M | 317.87%5.8M | ---- | --2.91M | 373.27%1.39M |
Net profit of parent company owners | 4.23%839.81M | 4.27%649.61M | 5.92%419.64M | 28.51%805.75M | 33.70%622.99M | 57.45%396.2M | 77.71%627M | --465.95M | --251.63M | 59.34%352.82M |
Earning per share | ||||||||||
Basic earning per share | 4.22%2.47 | 4.37%1.91 | 5.13%1.23 | 28.80%2.37 | --1.83 | 58.11%1.17 | 65.77%1.84 | ---- | --0.74 | 50.00%1.11 |
Diluted earning per share | 4.22%2.47 | 4.37%1.91 | 5.13%1.23 | 28.80%2.37 | --1.83 | 58.11%1.17 | 65.77%1.84 | ---- | --0.74 | 50.00%1.11 |
Other composite income | 2.27%8.95M | -122.67%-3.18M | -76.87%3.93M | -61.39%8.75M | 14.03M | 31.12%16.99M | 520.79%22.66M | 12.96M | 39.06%-5.39M | |
Other composite income of parent company owners | 2.27%8.95M | -122.67%-3.18M | -76.87%3.93M | -61.39%8.75M | --14.03M | 31.12%16.99M | 520.79%22.66M | ---- | --12.96M | 39.06%-5.39M |
Total composite income | 4.83%865.57M | 1.90%657.66M | 3.12%431.12M | 25.97%825.68M | 645.39M | 56.28%418.06M | 87.91%655.46M | 267.51M | 63.86%348.82M | |
Total composite income of parent company owners | 4.21%848.76M | 1.48%646.43M | 2.51%423.57M | 25.37%814.5M | --637.02M | 56.16%413.19M | 86.99%649.66M | ---- | --264.59M | 63.44%347.43M |
Total composite income of minority owners | 50.33%16.81M | 34.19%11.23M | 54.82%7.55M | 92.78%11.18M | --8.37M | 67.20%4.87M | 317.87%5.8M | ---- | --2.91M | 373.27%1.39M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | Unqualified opinion | -- | -- | Unqualified opinion | -- | -- | Unqualified opinion | -- | -- | Unqualified opinion |
Auditor | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | Lixin Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.